According to information from Interfax of Ukraine, Ukrainian patients and doctors are waiting for registration of the domestic generic drug with the active substance “sildenafil” for the treatment of pulmonary hypertension (PH).
“For today, a domestic generic drug has been created which, I think, will take its leading place after all official registration procedures, it will reduce costs for sildenafil (imported – IF) due to the fact that it is domestic.This will increase the cost of other new drugs” , – said the head of the Center for Pulmonary Hypertension at the Institute of Cardiology im. academician Strazhesko Yuri Sirenko at a briefing on Friday.
He specified that the drug produced by the Ukrainian company “Microkhim” (Rubezhnoye, Lugansk region) can be registered before the end of this year. Y. Syrenko noted that at the moment only three drugs are registered in Ukraine, several more are undergoing registration procedures. At the same time in developed countries, the number of drugs for the treatment of this disease is much higher.
In total, the European Medicines Agency (EMA), as well as the US Food and Drug Administration (FDA), registered about 15 drugs for PH treatment.
In turn, the chairman of the board of the Ukrainian Association of Patients with Pulmonary Hypertension Oksana Aleksandrova, commenting on the problems of treatment of patients with PH, focused on the need to increase the amount of funding from the state budget for the purchase of drugs.
“In 2016, under the state program, 75 million UAH was allocated, this year the number of patients is twice as high, but the budget program remained at the same level,” she said.
In addition, O. Alexandrova also noted that the drugs that were purchased for the state budget funds in 2016 became available to patients only last year.
“We have not received a single tablet for the budget-2017. Interruption of treatment is critically dangerous for patients,” she said.
The biggest problem, according to the chairman of the association’s board, for Ukrainian patients with LH is the absence of lung transplantation, as well as the heart-lung complex. At the same time, patients who receive such medical assistance abroad, when they return to Ukraine, do not have adequate access to appropriate medical services necessary in the post-transplant period.
At the same time, Oleksandrova noted that over the past three years positive changes have been observed in the treatment of patients with PH.
“We have doctors who can correctly diagnose this disease, and most importantly, we have the Center for Pulmonary Hypertension for Adults at the Strazhesko Institute, as well as the Center for Pulmonary Hypertension for Children at the Institute of Pediatric Cardiology and Cardiac Surgery,” she said.
According to the “Ukrainian Association of Patients with Pulmonary Hypertension,” in Ukraine, currently officially registered 470 patients with this disease. In this case, according to Y.Syrenko, the disease was diagnosed only in 1/10 of patients. The monthly cost of treatment for one patient with PH is from 30 thousand UAH to 150 thousand UAH.